(VIANEWS) - ICON plc (ICLR), The Joint Corp. (JYNT), Caesarstone Ltd. (CSTE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. ICON plc (ICLR)
141.3% sales growth and 3.68% return on equity
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
ICON plc's sales growth this year is expected to be 96.4% and 44.2% for next year.
Year-on-year quarterly revenue growth grew by 166%, now sitting on 4.36B for the twelve trailing months.
Volume
Today's last reported volume for ICON plc is 489396 which is 1.7% below its average volume of 497870.
ICON plc's sales growth for the next quarter is 141.3%. The company's growth estimates for the current quarter and the next is 37.9% and 23.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.68%.
Volatility
ICON plc's last day, last week, and last month's current intraday variation average was 4.27%, 2.16%, and 2.11%, respectively.
ICON plc's highest amplitude of average volatility was 4.83% (day), 3.13% (last week), and 3.69% (last month), respectively.
ICON plc's Stock Yearly Top and Bottom Value
ICON plc's stock is valued at $261.56 at 19:22 EST, way under its 52-week high of $313.00 and way above its 52-week low of $168.76.
ICON plc's Moving Average
ICON plc's value is under its 50-day moving average of $277.80 and higher than its 200-day moving average of $253.83.2. The Joint Corp. (JYNT)
42.2% sales growth and 91.29% return on equity
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States.
The Joint Corp.'s sales growth this year is expected to be 37.1% and 29.5% for next year.
Year-on-year quarterly revenue growth grew by 36.2%, now sitting on 75.8M for the twelve trailing months.
Volume
Today's last reported volume for The Joint Corp. is 91614 which is 44.44% below its average volume of 164904.
The Joint Corp.'s sales growth for the next quarter is 42.2%. The company's growth estimates for the present quarter and the next is a negative 93.1% and negative -62.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 91.29%.
Volatility
The Joint Corp.'s last day, last week, and last month's current intraday variation average was 3.01%, 2.87%, and 3.34%, respectively.
The Joint Corp.'s highest amplitude of average volatility was 5.94% (day), 5.61% (last week), and 6.98% (last month), respectively.
The Joint Corp.'s Stock Yearly Top and Bottom Value
The Joint Corp.'s stock is valued at $53.47 at 19:22 EST, way under its 52-week high of $111.06 and way above its 52-week low of $36.00.
The Joint Corp.'s Moving Average
The Joint Corp.'s worth is way below its 50-day moving average of $59.54 and way under its 200-day moving average of $77.98.3. Caesarstone Ltd. (CSTE)
19.2% sales growth and 3.85% return on equity
Caesarstone Ltd., together with its subsidiaries, develops, manufactures, and markets engineered quartz surfaces under the Caesarstone brand in the United States, Australia, Canada, Latin America, Asia, Israel, Europe, the Middle East, and Africa.
Caesarstone Ltd.'s sales growth this year is anticipated to be 29.7% and 10.5% for next year.
Year-on-year quarterly revenue growth grew by 31.8%, now sitting on 609.73M for the twelve trailing months.
Volume
Today's last reported volume for Caesarstone Ltd. is 154826 which is 32.1% above its average volume of 117200.
Caesarstone Ltd.'s sales growth for the next quarter is 19.2%. The company's growth estimates for the current quarter and the next is 20% and negative -50%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.85%.
Volatility
Caesarstone Ltd.'s last day, last week, and last month's current intraday variation average was 3.01%, 1.93%, and 1.55%, respectively.
Caesarstone Ltd.'s highest amplitude of average volatility was 4.09% (day), 3.65% (last week), and 3.47% (last month), respectively.
Caesarstone Ltd.'s Stock Yearly Top and Bottom Value
Caesarstone Ltd.'s stock is valued at $11.61 at 19:22 EST, way below its 52-week high of $19.80 and way above its 52-week low of $10.20.
Caesarstone Ltd.'s Moving Average
Caesarstone Ltd.'s worth is below its 50-day moving average of $11.72 and way under its 200-day moving average of $13.30.4. Antares Pharma (ATRS)
17.4% sales growth and 63.08% return on equity
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas.
Antares Pharma's sales growth this year is anticipated to be 22.1% and 23.2% for next year.
Year-on-year quarterly revenue growth grew by 20.5%, now sitting on 179.38M for the twelve trailing months.
Volume
Today's last reported volume for Antares Pharma is 1352880 which is 99.55% above its average volume of 677939.
Antares Pharma's sales growth for the next quarter is 17.4%. The company's growth estimates for the present quarter and the next is a negative 66.7% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 63.08%.
Volatility
Antares Pharma's last day, last week, and last month's current intraday variation average was 0.84%, 1.62%, and 1.95%, respectively.
Antares Pharma's highest amplitude of average volatility was 1.96% (day), 2.80% (last week), and 3.46% (last month), respectively.
Antares Pharma's Stock Yearly Top and Bottom Value
Antares Pharma's stock is valued at $3.62 at 19:22 EST, way under its 52-week high of $5.07 and way above its 52-week low of $3.11.
Antares Pharma's Moving Average
Antares Pharma's worth is above its 50-day moving average of $3.39 and below its 200-day moving average of $3.80.5. Orion Engineered Carbons S.A (OEC)
14.8% sales growth and 60.65% return on equity
Orion Engineered Carbons S.A., together with its subsidiaries, produces and sells carbon black products in Germany, the United States, South Korea, Brazil, China, South Africa, the rest of Europe, and internationally.
Orion Engineered Carbons S.A's sales growth this year is expected to be 36% and 10% for next year.
Year-on-year quarterly revenue growth grew by 39.4%, now sitting on 1.47B for the twelve trailing months.
Volume
Today's last reported volume for Orion Engineered Carbons S.A is 358507 which is 41.52% above its average volume of 253324.
Orion Engineered Carbons S.A's sales growth for the next quarter is 14.8%. The company's growth estimates for the present quarter and the next is a negative 12.5% and 3.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 60.65%.
Volatility
Orion Engineered Carbons S.A's last day, last week, and last month's current intraday variation average was 0.16%, 2.16%, and 1.59%, respectively.
Orion Engineered Carbons S.A's highest amplitude of average volatility was 3.52% (day), 4.68% (last week), and 3.95% (last month), respectively.
Orion Engineered Carbons S.A's Stock Yearly Top and Bottom Value
Orion Engineered Carbons S.A's stock is valued at $18.53 at 19:22 EST, way under its 52-week high of $22.45 and way higher than its 52-week low of $15.51.
Orion Engineered Carbons S.A's Moving Average
Orion Engineered Carbons S.A's value is above its 50-day moving average of $17.97 and below its 200-day moving average of $18.66.6. Columbus McKinnon Corporation (CMCO)
10.1% sales growth and 4.41% return on equity
Columbus McKinnon Corporation designs, manufactures, and markets intelligent motion solutions to ergonomically move, lift, position, and secure materials worldwide.
Columbus McKinnon Corporation's sales growth this year is expected to be 36.8% and 10% for next year.
Year-on-year quarterly revenue growth grew by 29.7%, now sitting on 839.42M for the twelve trailing months.
Volume
Today's last reported volume for Columbus McKinnon Corporation is 107536 which is 7.14% above its average volume of 100366.
Columbus McKinnon Corporation's sales growth for the next quarter is 10.1%. The company's growth estimates for the ongoing quarter and the next is 56% and 17.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.41%.
Volatility
Columbus McKinnon Corporation's last day, last week, and last month's current intraday variation average was 1.10%, 1.49%, and 1.38%, respectively.
Columbus McKinnon Corporation's highest amplitude of average volatility was 2.37% (day), 3.74% (last week), and 4.18% (last month), respectively.
Columbus McKinnon Corporation's Stock Yearly Top and Bottom Value
Columbus McKinnon Corporation's stock is valued at $44.44 at 19:22 EST, way below its 52-week high of $57.06 and higher than its 52-week low of $41.01.
Columbus McKinnon Corporation's Moving Average
Columbus McKinnon Corporation's worth is below its 50-day moving average of $45.89 and below its 200-day moving average of $47.55.7. Owens Corning (OC)
7.5% sales growth and 24.49% return on equity
Owens Corning, together with its subsidiaries, produces and sells glass fiber reinforcements and other materials for composites; and residential, commercial, and industrial building materials worldwide.
Owens Corning's sales growth this year is expected to be 19.1% and 5.4% for next year.
Year-on-year quarterly revenue growth grew by 16.2%, now sitting on 8.29B for the twelve trailing months.
Volume
Today's last reported volume for Owens Corning is 267569 which is 72.91% below its average volume of 987798.
Owens Corning's sales growth for the next quarter is 7.5%. The company's growth estimates for the current quarter and the next is 0.5% and 5.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.49%.
Volatility
Owens Corning's last day, last week, and last month's current intraday variation average was 1.44%, 1.52%, and 1.81%, respectively.
Owens Corning's highest amplitude of average volatility was 3.44% (day), 2.56% (last week), and 3.50% (last month), respectively.
Owens Corning's Stock Yearly Top and Bottom Value
Owens Corning's stock is valued at $88.16 at 19:22 EST, way under its 52-week high of $109.90 and way higher than its 52-week low of $75.66.
Owens Corning's Moving Average
Owens Corning's value is below its 50-day moving average of $90.39 and under its 200-day moving average of $94.36.8. Royalty Pharma (RPRX)
6.2% sales growth and 15.4% return on equity
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
Royalty Pharma's sales growth this year is anticipated to be 5.6% and 3.5% for next year.
Year-on-year quarterly revenue growth grew by 8.8%, now sitting on 2.29B for the twelve trailing months.
Volume
Today's last reported volume for Royalty Pharma is 1098350 which is 41.51% below its average volume of 1878030.
Royalty Pharma's sales growth for the next quarter is 6.2%. The company's growth estimates for the ongoing quarter and the next is 41.7% and 171.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.4%.
Volatility
Royalty Pharma's last day, last week, and last month's current intraday variation average was 2.26%, 1.71%, and 1.26%, respectively.
Royalty Pharma's highest amplitude of average volatility was 2.29% (day), 1.98% (last week), and 2.53% (last month), respectively.
Royalty Pharma's Stock Yearly Top and Bottom Value
Royalty Pharma's stock is valued at $38.54 at 19:22 EST, way under its 52-week high of $53.23 and way above its 52-week low of $34.86.